NCT07511972

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

A Phase 2 Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: NGM Biopharmaceuticals, Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Conditions

• CRC

Interventions

Type	Name	Description
DRUG	NGM707 plus pembrolizumab	Drug: NGM707 NGM707 will be administered intravenously (IV) every 3 weeks in a 21 day cycle. Drug: pembrolizumab Pembrolizumab will be administered intravenously (IV) every 3 weeks in a 21 day cycle.

Timeline

• Start date: 2023-11-14
• Primary completion: 2024-12-31
• Completion: 2025-09-30
• First posted: 2026-04-06
• Last updated: 2026-04-06

Regulatory

• FDA-regulated drug study